Klin Farmakol Farm. 2008;22(3):99-102

Therapy of irritable bowel syndrome - actual possibilities

Jiří Ehrmann
II. interní klinika FN a LF UP Olomouc

Irritable bowel syndrome (IBS) is one of the most common gut functional diseases, affecting 10–20 % of people wordwide. Diagnosis is based on the identification of symptoms according to Rome II or Rome III criteria. The treatment of IBS is centred on an excellent doctor-patient relationship. Approximately 70 % patients have only mild symptoms and fundamental therapy is non-pharmacological aids, diet and psychological treatment or from time to time antispasmodics. Patients with moderate or sever form require pharmacological approaches to IBS., i.e. antispasmodics, antidiarrhoeals, antidepressants, SSRIs, prebiotics and probiotics. A variety of other new drugs are currently under investigation.

Keywords: Key words: irritable bowel syndrome, non-pharmacological treatment, pharmacological treatment.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ehrmann J. Therapy of irritable bowel syndrome - actual possibilities. Klin Farmakol Farm. 2008;22(3):99-102.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kment M. Diagnostická úskalí dráždivého tračníku. In Lukáš K a kol. Funkční poruchy trávicího traktu. Praha: Grada, 2003: 92-100.
    2. Barbara G, DeGiorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irriatable bowel syndrome. Aliment Pharmacol Ther 2004; 20 (Suppl.2): 1-9. Go to original source... Go to PubMed...
    3. Camilleri M, Heading RC, Thompson WG. Clinical perspectives, mechanism, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1407-1430. Go to original source... Go to PubMed...
    4. DeGiorgio R, Barbara G, Stanghellini V, et al. Diagnosis and therapy of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 (Suppl 2): 10-22. Go to original source... Go to PubMed...
    5. Thompson WG, Longstrech G, Drossman DA, el al. Functional Bowel Disorderas and Functional Abdominal Pain. In ed. Drossman DA. The Functional Gastrointestinal Disorders. 2nd ed. Virginia, USA: Degnon Associates McLean, 2000: 351-409. Go to original source...
    6. Douglas A, Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1337-1390. Go to original source...
    7. Ehrmann J. Funkční střevní poruchy - Římská kriteria II. Postgrad Med 2001; 3: 267-270.
    8. Snook J, Shepherd HA. Bransupplementation in treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 511-514. Go to original source... Go to PubMed...
    9. British Medical Association Report. Medical use of hypnotism. BJM 1955; 1 (Suppl.): 190-193.
    10. Hilgard ER. Hypnotic Susceptibility. New York: Harcourt. Brace & World. Inc. 1965.
    11. Kratochvíl S. Gastrointestinální poruchy. In. Kratochvíl S. Klinická hypnóza, 2. přepr. vyd. Praha: Grada, 2001: 186-192.
    12. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of sever refractory irritable bowel syndrome. Lancet 1984; ii: 1232-1234. Go to original source... Go to PubMed...
    13. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002; 97: 954-961. Go to original source... Go to PubMed...
    14. Gonsalkorale WM, Miller A, Afzal A. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003; 52: 1623-1629. Go to original source... Go to PubMed...
    15. Whorwell PJ. Review article: the history of hypnotherapy and its role in the irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 1061-1067. Go to original source... Go to PubMed...
    16. Jirásek V. Terapie funkčních poruch trávicí trubice. In Lukáš K. a kol. Funkční poruchy trávícího traktu Praha: Grada, 2003: 101-121.
    17. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials. Ann Intern Med 2000; 133: 136-147. Go to original source... Go to PubMed...
    18. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin 3 receptor antagonist alosetron in women with diarrhea-pedominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-1740. Go to original source... Go to PubMed...
    19. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86. Go to original source... Go to PubMed...
    20. Cash BD, Chey WD. Review article: the role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther 2005; 22: 1047-1060. Go to original source... Go to PubMed...
    21. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002; 122: 1701-1714. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.